Medication-assisted treatment for substance use disorders within a national community health center research network

References

• Sigmon SC, Bisaga A, Nunes EV, O’Connor PG, Kosten T, Woody G. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse. 2012;38:187–199.
   PubMed Web of Science ®Google Scholar
• Ghitza HE, Tai B. Challenges and opportunities for integrating preventive substance-use-care services in primary care through the Affordable Care Act. J Health Care Poor Underserved. 2014;25:36–45.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA). Results From the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. NSDUH Series H-48, HHS Publication No. (SMA) 14–4863. http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf. Published September 2014. Accessed May 29, 2015.
   Google Scholar
• Moses K, Klebonis J; Centers for Medicare and Medicaid Services. Designing Medicaid health homes for individuals with opioid dependency: considerations for states. http://www.chcs.org/media/HH-IRC-Health-Homes-for-Opioid-Dependency.pdf. Published January 2015. Accessed May 27, 2015.
   Google Scholar
• National Institute on Drug Abuse (NIDA). Drug facts: treatment statistics. http://www.drugabuse.gov/publications/drugfacts/treatment-statistics. Revised March 2011. Accessed May 6, 2015.
   Google Scholar
• Amato L, Mitrova Z, Davoli M. Cochrane systematic reviews in the field of addiction: past and future. J Evid Based Med. 2013;6:221–228.
   PubMedGoogle Scholar
• Rehm J, Gnam W, Popova S, et al. The costs of alcohol, illegal drugs, and tobacco in Canada, 2002. J Stud Alcohol Drug. 2007;68:886–895.
   Google Scholar
• Manchikanti L, Fellows, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010;13:401–435.
   PubMed Web of Science ®Google Scholar
• Rinaldo SG, Rinaldo DW; The American Society of Addiction Medicine. Advancing access to addiction medications: implications for opioid addiction treatment. http://www.asam.org/docs/default-source/advocacy/aaam_implications-for-opioid-addiction-treatment_final. Published June 2013. Accessed May 27, 2015.
   Google Scholar
• Centers for Disease Control and Prevention. Alcohol Related Disease Impact (ARDI) application. http://nccd.cdc.gov/DPH_ARDI/default/Default.aspx. Accessed May 27, 2015.
   Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA). National Expenditures for Mental Health Services and Substance Abuse Treatment, 1986–2009. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013. HHS Publication No. SMA-13-4740. https://store.samhsa.gov/shin/content/SMA13-4740/SMA13-4740.pdf. Published 2013. Accessed May 27, 2015.
   Google Scholar
• Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerwattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373:2223–2233.
   PubMed Web of Science ®Google Scholar
• Taylor B, Irving HM, Baliunas D, et al. Alcohol and hypertension: gender differences in dose–response relationships determined through systematic review and meta-analysis. Addiction.  2009;104:1981–1990.
   PubMed Web of Science ®Google Scholar
• Banerjea R, Sambamoorthi U, Smelson D, Pogach LM. Chronic illness with complexities: mental illness and substance use among Veteran clinic users with diabetes. Am J Drug Alcohol Abuse. 2007;33:807–821.
   PubMed Web of Science ®Google Scholar
• Beaglehole R, Bonita R. Alcohol: a global health priority. Lancet. 2009;373:2173–2174.
   PubMed Web of Science ®Google Scholar
• Bouchery EE, Harwood HJ, Sacks JJ, Simon CJ, Brewer RD. Economic costs of excessive alcohol consumption in the US, 2006. Am J Prev Med. 2011;41:516–524.
   PubMed Web of Science ®Google Scholar
• Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2014;61:807–816.
   Web of Science ®Google Scholar
• Thornton LK, Baker AL, Lewin TJ, et al. Reasons for substance use among people with mental disorders. Addict Behav. 2012;37:427–434.
   PubMed Web of Science ®Google Scholar
• Robinson J, Sareen J, Cox BJ, Bolton JM. Role of self-medication in the development of comorbid anxiety and substance use disorders: a longitudinal investigation. Arch Gen Psychiatry. 2011;68:800–807.
   PubMed Web of Science ®Google Scholar
• Birrell L, Newton NC, Teesson M, Tonks Z, Slade T. Anxiety disorders and first alcohol use in the general population. Findings from a nationally representative sample. J Anxiety Disord. 2015;31:108–113.
   Google Scholar
• Morasco BJ, Gritzner S, Lewis L, Oldham R, Turk DC, Dobscha SK. Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder. Pain. 2011;152:488–497.
   PubMed Web of Science ®Google Scholar
• Batki SL, Meszaros ZS, Strutynski K, et al. Medical comorbidity in patients with schizophrenia and alcohol dependence. Schizophr Res. 2009;107:139–146.
   PubMed Web of Science ®Google Scholar
• Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655–661.
   PubMed Web of Science ®Google Scholar
• Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.
   PubMed Web of Science ®Google Scholar
• Nelson PK, Mathers BM, Cowie B, Jarlas DD, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571–583.
   PubMed Web of Science ®Google Scholar
• Stein MD. Medical consequences of substance abuse. Pyschiatr Clin N Am. 1999;22:351–370.
   PubMed Web of Science ®Google Scholar
• Lee J, Kresina TF, Campopiano M, Lubran R, Clark HW. Use of pharmacotherapies in the treatment of alcohol use disorders and opioid dependence in primary care. BioMed Res Int. 2015;2015:137020. doi: 10.1155/2015/137020. Accessed May 29, 2015.
   PubMed Web of Science ®Google Scholar
• Bonhomme J, Shim RS, Gooden R, Tyus D, Rust G. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options. J Natl Med Assoc. 2012;104:342–350.
   Google Scholar
• Jan S, Gill P, Borawala AS. Utilization patterns of extended-release naltrexone for alcohol dependence. Am J Manag Care. 2011;17:S210–S212.
   Google Scholar
• Haddad MS, Zelenev A, Altice FL. Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers. J Urban Health. 2015;92:193–213.
   PubMed Web of Science ®Google Scholar
• Khatri K, Haddad M, Anderson D. Project ECHO: replicating a novel model to enhance access to hepatitis C care in a community health center. J Health Care Poor Underserved. 2013;24:850–858.
   PubMed Web of Science ®Google Scholar
• Saxon AJ, Hser YI, Woody G, Ling W. Medication-assisted treatment for opioid addiction: methadone and buprenorphine. J Food Drug Anal. 2013;21:S69–S72.
   PubMed Web of Science ®Google Scholar
• Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine–naloxone tablet. Drug Alcohol Depend. 2000;58:143–152.
   PubMed Web of Science ®Google Scholar
• Ling W, Wesson DR. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend. 2003;70:S49–S57.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;(2): CD002207. doi: 10.1002/14651858.CD002207.pub3. Accessed May 27, 2015.
   PubMed Web of Science ®Google Scholar
• Bezchlibnyk-Butler KZ, Jeffries JJ, Procyshyn RM, Virani AS. Clinical Handbook of Psychotropic Drugs. 2nd ed. Boston, MA: Hogrefe & Huber; 2007.
   Google Scholar
• Mello NK, Mendelson JH. Behavioral pharmacology of buprenorphine. Drug Alcohol Depend. 1985;14;283–303.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569–580.
   PubMed Web of Science ®Google Scholar
• Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174:1369–1376.
   PubMed Web of Science ®Google Scholar
• Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend. 1998;52:257–260.
   PubMed Web of Science ®Google Scholar
• Yancovitz SR, Des Jarlais DC, Peyser NP, et al. A randomized trial of an interim methadone maintenance clinic. Am J Public Health. 1991;81:1185–1191.
   PubMed Web of Science ®Google Scholar
• Stancliff S, Joseph H, Fong C, Furst T, Comer SD, Roux P. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. J Addict Dis. 2012;31:278–287.
   PubMed Web of Science ®Google Scholar
• Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 1995;40:17–25.
   PubMed Web of Science ®Google Scholar
• Kakko J, Grönbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry. 2007;164:797–803.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Hillhouse M, Weiss RD, et al. The relationship between primary prescription opioid and buprenorphine–naloxone induction outcomes in a prescription opioid dependent sample. Am J Addict. 2014;23:343–348.
   PubMed Web of Science ®Google Scholar
• Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750–2755.
   PubMed Web of Science ®Google Scholar
• Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8:573–582.
   PubMed Web of Science ®Google Scholar
• Dean RL. The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence. Front Biosci. 2005;10:643–655.
   PubMed Web of Science ®Google Scholar
• O’Leary G, Borrow J, Weiss RD. Opioid antagonist in the treatment of alcohol dependence. Curr Drug Abuse Rev. 2001;3:484–488.
   Google Scholar
• O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881–887.
   PubMed Web of Science ®Google Scholar
• Volpicelli J, Krishnan-Sarin S, O’Malley S. Alcoholism pharmacotherapy. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology. Baltimore, MD: Lippincott Williams & Wilkins; 2002:1445–1459.
   Google Scholar
• Kranzler HR, Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25:1335–1341.
   PubMed Web of Science ®Google Scholar
• Garbutt JC, West SL, Carey TS, Tohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA. 1999;281:1318–1325.
   PubMed Web of Science ®Google Scholar
• Chick J, Gough K, Falkowski W, et al. Disulfiram treatment of alcoholism. Br J Psychiatry. 1992;161:84–89.
   PubMed Web of Science ®Google Scholar
• Boothby LA, Doerign PL. Acamprosate for the treatment of alcohol dependence. Clin Ther. 2005;27:695–714.
   PubMed Web of Science ®Google Scholar
• Elissen AM, Steuten LM, Lemmens LC, et al. Meta-analysis of the effectiveness of chronic care management for diabetes: investigating heterogeneity in outcomes. J Eval Clin Pract. 2013;19:753–762. doi:10.1111/j.1365–2753.2012.01817.
   PubMed Web of Science ®Google Scholar
• Kuo S, Bryce CL, Zgibor JC, Wolf DL, Roberts MS, Smith KJ. Cost-effectiveness of implementing the chronic care model for diabetes care in a military population. J Diabetes Sci Technol. 2011;5:501–513.
   PubMedGoogle Scholar
• Sunaert P, Bastiaens H, Nobels F, et al. Effectiveness of the introduction of a chronic care model-based program for type 2 diabetes in Belgium. BMC Health Serv Res. 2010;10:207.
   PubMed Web of Science ®Google Scholar
• Gallagher H, de Lusignan S, Harris K, Cates C. Quality-improvement strategies for the management of hypertension in chronic kidney disease in primary care: a systematic review. Br J Gen Pract. 2010;60:e258–e265.
   PubMed Web of Science ®Google Scholar
• Tai B, Volkow ND. Treatment for substance use disorder: opportunities and challenges under the Affordable Care Act. Soc Work Public Health. 2013;28:165–174.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Preventive services covered under the Affordable Care Act. http://www.hhs.gov/healthcare/facts/factsheets/2010/07/preventive-services-list.html. Published 2012. Accessed February 1, 2015.
   Google Scholar
• Mental Health Parity and Addiction Equity Act of 2008 (PL 110-460, 12/23/2008). Text from: Public Laws by Law Number. Available from: Thomas (Library of Congress), http://thomas.loc.gov. Accessed May 27, 2015.
   Google Scholar
• Swenson-Britt E, Carrougher G, Martin BW, Brackley M. Project hope: changing care delivery for the substance abuse patient. Clin Nurse Spec. 2000;14:92–100.
   PubMedGoogle Scholar
• Bowman S, Eiserman J, Beletsky L, Stancliff S, Bruce RD. Reducing the health consequences of opioid addiction in primary care. Am J Med. 2013;126:565–571.
   PubMed Web of Science ®Google Scholar
• Tai B, Saxon AJ, Ling W. Medication-assisted therapy for opioid addiction. J Food Drug Anal. 2013;21:S13-S15.
   Web of Science ®Google Scholar
• Laws R, Gillespie S, Puro J, et al. The community health applied research network (CHARN) data warehouse: a resource for patient-centered outcomes research and quality improvement in underserved, safety net populations. eGEMs. 2014;2:11. doi:10.13063/2327-9214.1097
   Google Scholar
• Likumahuwa S1, Song H, Singal R, et al. Building research infrastructure in community health centers: a Community Health Applied Research Network (CHARN) report. J Am Board Fam Med. 2013;26:579–587. doi:10.3122/jabfm.2013.05.130025.
   PubMed Web of Science ®Google Scholar
• Guo G, Zhao HX. Multilevel modeling for binary data. Annu Rev Sociol. 2000;26:441–462.
   Web of Science ®Google Scholar
• McCulloch CE, Searle SR, Neuhaus JM. Generalized, Linear, and Mixed Models. 2nd ed. Hoboken, NJ: Wiley; 2008.
   Google Scholar
• Raudenbush SW, Bryk AS. Hierarchical Linear Models: Applications and Data Analysis Methods. 2nd ed. Thousand Oaks, CA: Sage Publications; 2002.
   Google Scholar
• Liu Q, Pierce DA. A note on gauss-hermite quadrature. Biometrika. 1994;81:624–629.
   Web of Science ®Google Scholar
• Rabe-Hesketh S, Skrondal A, Pickles A. Maximum likelihood estimation of limited and discrete dependent variable models with nested random effects. J Econometr. 2005;128:301–323.
   Web of Science ®Google Scholar
• National Center on Addiction and Substance Abuse. Missed Opportunity: CASA National Survey of Primary Care Physicians and Patients on Substance Abuse. New York, NY: Columbia University, CASA; 2000. http://www.casacolumbia.org/addiction-research/reports/national-survey-primary-care-physicians-patients-substance-abuse. Published May 2000. Accessed May 28, 2015.
   Google Scholar
• Muench J. Screening and brief intervention practice systems and implementation. In: Saitz R, ed. Addressing Unhealthy Alcohol Use in Primary Care. New York, NY: Springer; 2013:171–188.
   Google Scholar
• Spandorfer JM, Israel Y, Turner BJ. Primary care physicians’ views on screening and management of alcohol abuse: inconsistencies with national guidelines. J Fam Pract. 1999;48:899–902
   PubMed Web of Science ®Google Scholar
• Cook BL, Alegria M. Racial-ethnic disparities in substance abuse treatment: the role of criminal history and socioeconomic status. Psychiatr Serv. 2011;62:1273–1281.
   PubMed Web of Science ®Google Scholar
• Evon DM, Simpson KM, Esserman D, Verma A, Smith S, Fried MW. Barriers to accessing care in patients with chronic hepatitis C: the impact of depression. Aliment Pharmacol Ther. 2010;32:1163–1173.
   PubMed Web of Science ®Google Scholar
• Reif S, Golin CE, Smith SR. Barriers to accessing HIV/AIDS care in North Carolina: rural and urban differences. AIDS Care. 2005;17:558–565.
   PubMed Web of Science ®Google Scholar
• Fernández A, Rubio-Valera M, Bellón JA, et al. DASMAP investigators. Recognition of anxiety disorders by the general practitioner: results from the DASMAP study. Gen Hosp Psychiatry. 2012;34:227–233.
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Kessler RC, Beesdo K, Krause P, Höfler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002;63(Suppl 8):24–34.
   PubMed Web of Science ®Google Scholar
• Vermani M, Marcus M, Katzman MA. Rates of detection of mood and anxiety disorders in primary care: a descriptive, cross-sectional study. Prim Care Companion CNS Disord. 2011;13:e1-e10.
   PubMedGoogle Scholar
• O’Cleirigh C, Magidson JF, Skeer M, Mayer KH, Safren SA. Prevalence of psychiatric and substance abuse symptomatology among HIV-infected gay and bisexual men in HIV primary care. Psychosomatics. 2015; 56(5): 470–478.
   Web of Science ®Google Scholar
• Israelski DM, Prentiss DE, Lubega S, et al. Psychiatric co-morbidity in vulnerable populations receiving primary care for HIV/AIDS. AIDS Care. 2007;19:220–225.
   PubMed Web of Science ®Google Scholar
• Robinson J, Sareen J, Cox BJ, Bolton J. Self-medication of anxiety disorders with alcohol and drugs: results from a nationally representative sample. J Anxiety Disord. 2009;23:38–45.
   PubMed Web of Science ®Google Scholar
• Hasin D, Kilcoyne B. Comorbidity of psychiatric and substance use disorders in the United States: current issues and findings from the NESARC. Curr Opin Psychiatry. 2012;25:165–171.
   PubMed Web of Science ®Google Scholar
• Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67:247–257.
   PubMed Web of Science ®Google Scholar
• Lydiard BR, Brady K, Ballenger JC, Howell EF, Malcolm R. Anxiety and mood disorders in hospitalized alcoholic individuals. Am J Addict. 1992;1:325–331.
   Google Scholar
• Branson BM, Handsfield HH, Lampe MA. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17; quiz CE11–CE14.
   PubMedGoogle Scholar
• Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:101–108.
   Google Scholar
• Colvin HM, Mitchell AE. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press; 2010. http://www.cdc.gov/hepatitis/PDFs/IOM-HepatitisAndLiverCancerReport.pdf. Accessed May 28, 2015.
   Google Scholar
• Mayer KH, Crawford P, Dant L, Gillespite S, Vandermeer M, Muench J, Long T, Quach T, Chaudhry A, Crane HM, Lembdo D, Mills R, McBurnie MA. HIV and Hepatitis C Virus screening practices among primary care providers in a geographically diverse sample of U.S. community health centers. AIDS Patient Care STDS. 2016; 30(6): 237–246.
   Google Scholar
• Rieckmann T, Gideonse N, Risser A, Devoe JE, Abraham A. Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data. Journal of Behavioral Health Services & Research. Under Review.
   Google Scholar
• Tkacz J, Severt J, Cacciola J, Ruetsch C. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. Am J Addict. 2012;21:55–62.
   PubMed Web of Science ®Google Scholar